The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Open accessAbstract
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 ( IDH1 ) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic and molecular markers of malignant tumors have been integrated into clinical practice 5,6 , with the US Food and Drug Administration (FDA) providing approval for several companion diagnostic devices and nucleic acid-based tests 7,8 .”
From Multimodal biomedical AI (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein, a negative regulator of PI3K signaling (6–8).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“The IDH genes (IDH1 and IDH2) encode isocitrate dehydrogenases, and mutations in these genes are among the most frequent found in diffuse gliomas118,119.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [118]
In the citing paper
“Moreover, in the context of DNA damage, MDM2 localizes to the nucleus and modulates DNA repair in a p53-independent manner by binding to and inactivating Nbs1 in the MRE11/Rad50/NBS1 complex.1,8,27”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [27]
In the citing paper
“Cancer genome sequencing efforts yielded an unexpected discovery in 2008 with the identification of somatic mutations in a metabolic enzyme, the TCA cycle enzyme IDH1, in glioblastoma multiforme (GBM) (77).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [77]
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the presence of IDH1/2 mutations in gliomas is associated with both lower histological grade and a slower rate of disease progression”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationSerial Analysis of Gene Expression
Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995) · Science · doi:10.1126/science.270.5235.484 · Cited by 3,713
Self-citationHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Self-citation
Flagged first, then by citations
4 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- H. Scherer, Am. J. Cancer40, 159 (1940).
- R. J. Learyet al. Proc. Natl. Acad. Sci. U.S.A. in press.
- K. Uekiet al., Cancer Res.56, 150 (1996).
- L. Frederick, X. Y. Wang, G. Eley, C. D. James, Cancer Res.60, 1383 (2000).
- G. Thielet al., Anticancer Res.15, 2495 (1995).
- S. Ekins, Y. Nikolsky, A. Bugrim, E. Kirillov, T. Nikolskaya, Methods Mol. Biol.356, 319 (2007).
- Contact information for the authors who directed the major components of this project is as follows: H. Yan G. J. Riggins (clinical and sample coordination) yan00002@mc.duke.edu griggin1@jhmi.edu; D. D. Bigner (pathological and clinical review) bigne001@mc.duke. edu; R. Karchin (bioinformatic analysis) karchin@jhu.edu; N. Papadopoulos (gene expression analysis) npapado1@jhmi.edu; G. Parmigiani (statistical analysis) gp@jhu.edu; B. Vogelstein V. E. Velculescu K. W. Kinzler (sequencing and copy number analysis) bertvog@gmail.com velculescu@jhmi.edu kinzlke@jhmi.edu. We thank N. Silliman J. Ptak L. Dobbyn and M. Whalen for assistance with PCR amplification; D. Lister L. J. Ehinger D. L. Satterfield J. D. Funkhouser and P. Killela for assistance with DNA purification; T. Sjöblom for assistance with database management; the Agencourt sequencing team for assistance with automated sequencing; and C.-S. Liu and the SoftGenetics team for their assistance with mutation detection analyses. This project was carried out under the auspices of the Ludwig Brain Tumor Initiative and was supported by the Virginia and D. K. Ludwig Fund for Cancer Research NIH grants CA121113 NS052507 CA43460 CA57345 CA62924 CA09547 5P50-NS-20023 CA108786 and CA11898 the Pew Charitable Trusts the Pediatric Brain Tumor Foundation Institute the Hirschhorn Foundation Alex's Lemonade Stand Foundation the American Brain Tumor Association the American Society of Clinical Oncology the Brain Tumor Research Fund and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme Beckman Coulter and Exact Sciences Corporations B.V. V.E.V. and K.W.K. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.
Cited by
Sorted by citations
Items 901–1,000 of 1,034
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 124
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
Laffaire, J., Everhard, S., Idbaïh, A., Crinière, E., Marie, Y., de Reyniès, A., Schiappa, R., Mokhtari, K., Hoang‐Xuan, K., Sanson, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq110 · Cited by 121
Experimental models and tools to tackle glioblastoma
Robertson, F., Marqués‐Torrejón, M. Á., Morrison, G. M., & Pollard, S. M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.040386 · Cited by 127
Spitz melanoma is a distinct subset of spitzoid melanoma
Raghavan, S. S., Peternel, S., Mully, T. W., North, J. P., Pincus, L. B., LeBoit, P. E., McCalmont, T. H., Bastian, B. C., & Yeh, I. (2020) · Modern Pathology · doi:10.1038/s41379-019-0445-z · Cited by 125
Lambiv, W. L., Vassallo, I., Delorenzi, M., Shay, T., Diserens, A., Misra, A., Feuerstein, B. G., Murat, A., Migliavacca, E., Hamou, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor036 · Cited by 121
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Felsberg, J., Wolter, M., Seul, H., Friedensdorf, B., Goeppert, M., Sabel, M., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0647-4 · Cited by 121
Pollack, I. F. (2011) · Journal of Neurosurgery Pediatrics · doi:10.3171/2011.5.peds1178 · Cited by 120
Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications
Kohnken, R. A., Kodigepalli, K. M., & Wu, L. J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0446-6 · Cited by 128
Nikiforova, M. N., Wald, A. I., Melan, M. A., Roy, S., Zhong, S., Hamilton, R. L., Lieberman, F. S., Drappatz, J., Amankulor, N., Pollack, I. F., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov289 · Cited by 121
Zeng, A.-L., Yan, W., Liu, Y.-W., Wang, Z., Hu, Q., Nie, E., Xin Min, Z. H. O. U., Li, R., Wang, X.-F., Jiang, T., et al. (2017) · Oncogene · doi:10.1038/onc.2017.134 · Cited by 125
Mucosa-associated microbiota signature in colorectal cancer
Gao, R., Kong, C., Huang, L., Li, H., Qu, X., Liu, Z., Lan, P., Wang, J., & Qin, H. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3026-4 · Cited by 123
Wang, L., Tsutsumi, S., Kawaguchi, T., Nagasaki, K., Tatsuno, K., Yamamoto, S., Sang, F., Sonoda, K., Sugawara, M., Saiura, A., et al. (2011) · Genome Research · doi:10.1101/gr.123109.111 · Cited by 120
Pillay, V., Allaf, L., Wilding, A. L., Donoghue, J. F., Court, N. W., Greenall, S. A., Scott, A. M., & Johns, T. G. (2009) · Neoplasia · doi:10.1593/neo.09230 · Cited by 119
Fraser, M. E., Berlín, A., Bristow, R. G., & van der Kwast, T. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.020 · Cited by 123
Sjödahl, G., Lauss, M., Guðjónsson, S., Liedberg, F., Halldén, C., Chebil, G., Månsson, W., Höglund, M., & Lindgren, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018583 · Cited by 119
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Pemov, A., Li, H., Patidar, R., Hansen, N. F., Sindiri, S., Hartley, S. W., Wei, J. S., ELKAHLOUN, A. G., Chandrasekharappa, S. C., Program, N. C. S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.464 · Cited by 125
Esquenazi, Y., Friedman, E. R., Liu, Z., Zhu, J., Hsu, S. H., & Tandon, N. (2017) · Neurosurgery · doi:10.1093/neuros/nyw174 · Cited by 120
An autophagy‐related long non‐coding RNA signature for glioma
Luan, F., Chen, W., Chen, M., Yan, J., Chen, H., Yu, H., Liu, T., & Mo, L. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12601 · Cited by 119
Bagnyukova, T., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. A. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13738 · Cited by 122
Diverse modes of genomic alteration in hepatocellular carcinoma
Jhunjhunwala, S., Jiang, Z., Stawiski, E. W., Gnad, F., Liu, J., Mayba, O., Du, P., Diao, J., Johnson, S., Wong, K., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0436-9 · Cited by 118
MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review
Ahir, B. K., Ozer, H., Engelhard, H. H., & Lakka, S. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.003 · Cited by 120
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
Zahnreich, S., & Schmidberger, H. (2021) · Cancers · doi:10.3390/cancers13112607 · Cited by 132
Wolf, A., Agnihotri, S., Muñoz, D. M., & Guha, A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.06.007 · Cited by 120
Bayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 119
Tan, X., Wang, S., Zhu, L., Wu, C., Yin, B., Zhao, J., Yuan, J., Qiang, B., & Peng, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207787109 · Cited by 121
Cancer Missense Mutations Alter Binding Properties of Proteins and Their Interaction Networks
Nishi, H., Tyagi, M. G., Teng, S., Shoemaker, B. A., Hashimoto, K., Alexov, E. G., Wuchty, S., & Panchenko, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066273 · Cited by 117
Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma
Torrini, C., Nguyen, T. T. T., Shu, C., Mela, A., Humala, N., Mahajan, A., Seeley, E., Zhang, G., Westhoff, M., Karpel‐Massler, G., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.06.030 · Cited by 117
Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024
Du, Y., Bian, Y., Baecker, D., Dhawan, G., Semghouli, A., Kiss, L., Zhang, W., Sorochinsky, A. E., Soloshonok, V. A., & Han, J. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202500662 · Cited by 124
Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma
Locasale, J. W., Melman, T., Song, S., Yang, X., Swanson, K. D., Cantley, L. C., Wong, E. T., & Asara, J. M. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014688 · Cited by 117
Müller, T., Gessi, M., Waha, A., Isselstein, L., Luxen, D., Freihoff, D., Freihoff, J., Becker, A. J., Simon, M., Hammes, J., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.017 · Cited by 116
Bhujbal, S. V., de Vos, P., & Niclou, S. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.010 · Cited by 116
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 121
Zarei, M., Lal, S., Parker, S. J., Nevler, A., Gohar, A. V., Dukleska, K., Mambelli-Lisboa, N. C., Moffat, C., Blanco, F. F., Chand, S. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0015 · Cited by 119
Modrek, A. S., Golub, D., Khan, T. A., Bready, D., Prado, J., Bowman, C., Deng, J., Zhang, G., Rocha, P. P., Raviram, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.009 · Cited by 118
Ohka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abé, T., Nakasu, Y., Namba, H., Wakai, K., Fukui, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023332 · Cited by 116
Phosphatidylinositol 3-Kinase: The Oncoprotein
Vogt, P. K., Hart, J. R., Gymnopoulos, M., Jiang, H., Kang, S., Bader, A. G., Zhao, L., & Denley, A. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_80 · Cited by 117
Advances in the genetics of glioblastoma: are we reaching critical mass?
Purow, B. W., & Schiff, D. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.96 · Cited by 118
Natural products: a hope for glioblastoma patients
Vengoji, R., Macha, M. A., Batra, S. K., & Shonka, N. (2018) · Oncotarget · doi:10.18632/oncotarget.25175 · Cited by 117
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119
Schulte, J. D., Buerki, R. A., Lapointe, S., Molinaro, A. M., Zhang, Y., Villanueva-Meyer, J. E., Perry, A., Phillips, J. J., Tihan, T., Bollen, A. W., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa142 · Cited by 118
Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
Valcárcel-Jiménez, L., & Frezza, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02412-w · Cited by 117
Juratli, T. A., Kirsch, M., Robel, K., Soucek, S., Geiger, K. D., von Kummer, R., Schackert, G., & Krex, D. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0844-1 · Cited by 115
Feng, H., Hu, B., Liu, K.-W., Li, Y., Lu, X., Cheng, T., Yiin, J., Lu, S., Keezer, S. M., Fenton, T. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58559 · Cited by 117
RetractedChotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 116
The new WHO 2016 classification of brain tumors—what neurosurgeons need to know
Banan, R., & Hartmann, C. J. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-016-3062-3 · Cited by 114
Hallal, S. M., Mallawaaratchy, D. M., Wei, H., Ebrahimkhani, S., Stringer, B. W., Day, B. W., Boyd, A., Guillemin, G. J., Buckland, M. E., & Alexander, K. L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1385-1 · Cited by 119
Wu, H., Guo, C., Wang, C., Xu, J., Zheng, S., Duan, J., Li, Y., Bai, H., Xu, Q., Ning, F., et al. (2023) · Cancer Science · doi:10.1111/cas.15773 · Cited by 116
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
Duncan, C. G., Killela, P. J., Payne, C. A., Lampson, B. L., Chen, W., Liu, J., Solomon, D. A., Waldman, T. A., Towers, A. J., Gregory, S. G., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.137 · Cited by 114
Self-citationPillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 113
Molecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 124
TERT Promoter Alterations in Glioblastoma: A Systematic Review
Olympios, N., Gilard, V., Marguet, F., Clatot, F., Fiore, F. D., & Fontanilles, M. (2021) · Cancers · doi:10.3390/cancers13051147 · Cited by 125
Broniscer, A., Tatevossian, R., Sabin, N. D., Klimo, P. D., Dalton, J., Lee, R. P., Gajjar, A. J., & Ellison, D. W. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12093 · Cited by 114
Human genetics and genomics a decade after the release of the draft sequence of the human genome
Naidoo, N., Yudi Pawitan, Y., Soong, R., Cooper, D. N., & Ku, C. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-577 · Cited by 117
Desideri, E., Vegliante, R., & Ciriolo, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.023 · Cited by 116
Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112
Self-citationHominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma
Chen, R., Nishimura, M. C., Kharbanda, S., Peale, F., Deng, Y., Daemen, A., Forrest, W. F., Kwong, M., Hedehus, M., Hatzivassiliou, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409653111 · Cited by 112
Combs, S. E., Rieken, S., Wick, W., Abdollahi, A., von Deimling, A., Debus, J., & Hartmann, C. J. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-115 · Cited by 112
Abou‐El‐Ardat, K., Seifert, M., Becker, K., Eisenreich, S., Lehmann, M., Hackmann, K., Rump, A., Meijer, G. A., Carvalho, B. G., Temme, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now231 · Cited by 114
Mutant IDH1 Promotes Glioma Formation In Vivo
Philip, B., Yu, D. X., Silvis, M. R., Shin, C., Robinson, J. P., Robinson, G. L., Welker, A., Angel, S. N., Tripp, S. R., Sonnen, J. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.133 · Cited by 112
Comba, A., Faisal, S. M., Dunn, P., Argento, A. E., Hollon, T. C., Al‐Holou, W. N., Varela, M. L., Zamler, D. B., Quass, G. L., Apostolides, P. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31340-1 · Cited by 123
Tumor metabolism as modulator of immune response and tumor progression
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.009 · Cited by 115
Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis
Camelo-Piragua, S. I., Jansen, M., Ganguly, A., Kim, J. C., Louis, D. N., & Nutt, C. L. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0632-y · Cited by 111
The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
Zhang, K., Wang, X., Zhou, B., & Zhang, L. (2013) · Familial Cancer · doi:10.1007/s10689-013-9607-1 · Cited by 111
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Chan, A. K., Yao, Y., Zhang, Z., Chung, N. Y., Liu, J. S.-M., Li, K. K., Shi, Z., Chan, D. T. M., Poon, W. S., Zhou, L., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.94 · Cited by 111
Weber, G. L., Parat, M., Binder, Z. A., Gallia, G. L., & Riggins, G. J. (2011) · Oncotarget · doi:10.18632/oncotarget.346 · Cited by 113
Self-citationAdvancing a clinically relevant perspective of the clonal nature of cancer
Ruiz, C. F., Lenkiewicz, E., Evers, L., Holley, T., Robeson, A., Kiefer, J., Demeure, M. J., Hollingsworth, M. A., Shen, M., Prunkard, D. E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104009108 · Cited by 111
Zhang, J., Liu, H., Tong, H., Wang, S., Yang, Y., Liu, G., & Zhang, W. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/7064120 · Cited by 111
The classification of gliomas based on a Pyramid dilated convolution resnet model
Lu, Z., Bai, Y., Chen, Y., Su, C., Lu, S., Zhan, T., Hong, X., & Wang, S. (2020) · Pattern Recognition Letters · doi:10.1016/j.patrec.2020.03.007 · Cited by 112
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 116
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis
Nakajima, H., & Kunimoto, H. (2014) · Cancer Science · doi:10.1111/cas.12484 · Cited by 117
Identification of rare cancer driver mutations by network reconstructionPreprint
Torkamani, A., & Schork, N. J. (2009) · Genome Research · doi:10.1101/gr.092833.109 · Cited by 115
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110
A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells
Mao, D. D., Gujar, A. D., Mahlokozera, T., Chen, I., Pan, Y., Luo, J. R., Brost, T. M., Thompson, E. A., Turski, A., Leuthardt, E. C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.027 · Cited by 113
Detection of IDH1 mutation in the plasma of patients with glioma
Boisselier, B., Pérez‐Larraya, J. G., Rossetto, M., Labussière, M., Ciccarino, P., Marie, Y., Delattre, J., & Sanson, M. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e9b0a · Cited by 110
LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
da Silva, R., Uno, M., Marie, S. K. N., & Oba‐Shinjo, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119781 · Cited by 110
Self-citationFojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
Quantitative sodium MR imaging: A review of its evolving role in medicine
Thulborn, K. R. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.11.056 · Cited by 116
Li, Z., Bai, H., Sun, Q., Zhao, Y., Lv, Y., Zhou, J. H., Liang, C., Chen, Y., Liang, D., & Zheng, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1863 · Cited by 112
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 113
Glutamate in cancers: from metabolism to signaling
Yi, H., Talmon, G., & Wang, J. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20190037 · Cited by 117
Fukushima, S., Otsuka, A., Suzuki, T., Yanagisawa, T., Mishima, K., Mukasa, A., Saito, N., Kumabe, T., Kanamori, M., Tominaga, T., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1247-5 · Cited by 110
Preusser, M., Wöehrer, A., Stary, S., Höftberger, R., Streubel, B., & Hainfellner, J. A. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822713f0 · Cited by 109
Stechishin, O. D. M., Luchman, H. A., Ruan, Y., Blough, M. D., Nguyen, S. A., Kelly, J. J., Cairncross, J. G., & Weiss, S. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos302 · Cited by 110
Liu, Y., Shete, S. S., Etzel, C. J., Scheurer, M. E., Alexiou, G. Α., Armstrong, G., Tsavachidis, S., Liang, F., Gilbert, M. R., Aldape, K. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6213 · Cited by 109
Dejeans, N., Pluquet, O., Lhomond, S., Grise, F., Bouchecareilh, M., Juin, A., Cadars, M., Bidaud-Meynard, A., Gentil, C., Moreau, V., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.099291 · Cited by 109
A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG
Pietrak, B., Zhao, H., Qi, H., Quinn, C. J., Gao, E. N., Boyer, J. G., Concha, N. O., Brown, K., Duraiswami, C., Wooster, R. F., et al. (2011) · Biochemistry · doi:10.1021/bi200499m · Cited by 112
Wu, H., Ying, M., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9746 · Cited by 114
Targeting Cancer Metabolism - Revisiting the Warburg Effects
Tran, Q., Lee, H., Park, J., Kim, S., & Park, J. (2016) · Toxicological Research · doi:10.5487/tr.2016.32.3.177 · Cited by 116
Current trends in mouse models of glioblastoma
Miyai, M., Tomita, H., Soeda, A., Yano, H., Iwama, T., & Hara, A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2626-2 · Cited by 109
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Liu, X., & Gong, Y. (2019) · Biomarker Research · doi:10.1186/s40364-019-0173-z · Cited by 111
Wang, Y., Wild, A. T., Turcan, Ş., Wu, W., Sigel, C., Klimstra, D. S., Ma, X., Gong, Y., Holland, E. C., Huse, J. T., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3221 · Cited by 109
Aging and Injury: Alterations in Cellular Energetics and Organ Function
Poulose, N. (2014) · Aging and Disease · doi:10.14336/ad.2014.0500101 · Cited by 109
Mitochondrial complex II, a novel target for anti-cancer agents
Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L., & Neuzil, J. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.015 · Cited by 104
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
McKnight, S. L. (2010) · Science · doi:10.1126/science.1199908 · Cited by 108
Emerging functions of microRNAs in glioblastoma
Lawler, S. E., & Chiocca, E. A. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9843-2 · Cited by 108
Altered Histone Modifications in Gliomas
Kim, Y. Z. (2014) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2014.2.1.7 · Cited by 116
Metadata
- Authors
- Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz, L. A., Hartigan, J., Smith, D. R., Strausberg, R. L., Marie, S. K. N., Shinjo, S. M. O., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
- Corresponding author
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Angenendt, Philipp
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- ORCID
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Carter, Hannah
- Gallia, Gary L.
- Olivi, Alessandro
- McLendon, Roger
- Keir, Stephen
- Diaz, Luis A.
- Marie, Suely Kazue Nagahashi
- Yan, Hai
- Riggins, Gregory J.
- Bigner, Darell D.
- Karchin, Rachel
- Parmigiani, Giovanni
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- Venue
- Science
- Published
- 2008-09-26
- Volume
- 321
- Issue
- 5897
- Pages
- 1807-1812
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2820389
- OpenAlex
- W2040827479
- Cited by
- 5,857
- References
- 51
- Citations by year
- 2026: 131 · 2025: 160 · 2024: 189 · 2023: 260 · 2022: 256 · 2021: 370 · 2020: 344 · 2019: 313 · 2018: 329 · 2017: 347 · 2016: 353 · 2015: 373 · 2014: 410 · 2013: 428 · 2012: 457
- FWCI
- 172.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca121113-15, 5p50ns020023-30)
- National Cancer Institute (CA108786., CA 57345, R01-CA121113, CA-121113, CA43460, CA-11898, R37CA043460, CA09547, P50CA108786, R01CA140316, P50CA062924, R37CA057345, T32CA009547, CA 62924)
- National Institute of Neurological Disorders and Stroke (5P50NS20023, R01NS052507, NS052507)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- glioblastoma, IDH1 mutation, IDH1, somatic mutations, gene amplification, gene deletion, gene expression profiling, secondary glioblastoma, overall survival, targeted therapy
- MeSH terms
- Adult, Brain Neoplasms, Female, Gene Amplification, Glioblastoma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Rate, Sequence Analysis, DNA, Gene Dosage, Mutation, Missense, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
